Unicycive Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.74 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 104.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Details
| Name | Unicycive Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 22 |
| Founded | 2016 |
| Ipo Date | 2021-07-13 |
| Ceo | Shalabh Gupta |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 5.00 |
| Isin | US90466Y2028 |
| Cusip | 90466Y202 |
| Cik | 0001766140 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Shalabh K. Gupta M.D., MPA | Founder, Chairman, Chief Executive Officer and President |
| Dr. Pramod Gupta Ph.D. | Executive Vice President of Pharmaceutical and Business Operations |
| Douglas Jermasek M.B.A. | Executive Vice President of Corporate Strategy |
| John W. Townsend CPA | Chief Financial Officer |
Contact
| Address | 1975 West El Camino Real, Suite 204, Mountain View, California 94040, United States |
| Phone | 650 351 4495 |
| Website | https://unicycive.com |